Corrigendum to “Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment” [Heliyon Volume 10, Issue

Authors

Shingo Kano (ORCID: https://orcid.org/0000-0002-6625-2644)
Naoko Shiraiwa (ORCID: https://orcid.org/0009-0003-5494-4314)

Institutions

The University of Tokyo (JP)

Publication Details

Journal: Heliyon
Published: 2025-11-20
DOI: https://doi.org/10.1016/j.heliyon.2025.e44157
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Corrigendum to “Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment” [Heliyon Volume 10, Issue

Shingo Kano, Naoko Shiraiwa

Nov 20, 2025

Heliyon

Lung Cancer Treatments and Mutations

article

Corrigendum to “Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment” [Heliyon Volume 10, Issue

Shingo Kano, Naoko Shiraiwa

November 20, 2025article en

Abstract

No abstract available for this paper.

HeliyonVol. 11(17)

The University of Tokyo (JP)

Openalex Percentile: Top 49%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Corrigendum to “Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment” [Heliyon Volume 10, Issue — Shingo Kano, Naoko Shiraiwa · Heliyon (2025) | TGRS Research Map | TGRS